
Cut the Clutter in Gynaecological Cancer Diagnosis
More than 60% of patients with cervical cancer and 30% of those with endometrial cancer are diagnosed at an advanced stage, when survival rates are lowest. Although intensifying screening may seem logical, unnecessary procedures can be harmful.
Routine procedures such as ultrasound, though often considered harmless, can lead to poorly indicated hysteroscopies and unnecessary biopsies, causing physical and psychological discomfort, warned Louise De Brot, MD, PhD, in the Department of Pathology, São Paulo, Brazil.
Therefore, prevention does not require as many clinical tests.
'The real challenge is applying screening to the population that will actually benefit from it,' explained Eduardo Batista Cândido, MD, PhD, president of the National Specialized Commission on Gynecologic Oncology of the Brazilian Federation of Gynecology and Obstetrics Associations (FEBRASGO).
This is the principle behind quaternary prevention, which avoids unnecessary medical interventions that may cause more harm than good. However, this can be challenging for healthcare professionals who lack confidence. Studies have shown that less experienced doctors, particularly those with less than 10 years of practice, are more likely to prescribe unnecessary tests, leading to higher costs for patients.
Cervical Screening
International and Brazilian guidelines, such as those from the Ministry of Health and the National Cancer Institute, recommend cervical cancer screening using oncotic cytology in women aged 25-64 years who are sexually active. After two consecutive normal results, screening may be repeated every 3 years.
In women aged under 25 years, human papillomavirus infections are often cleared without progressing to malignant disease. Cândido stated that 'If I identify a cellular alteration, I will have to perform a colposcopy, a targeted biopsy, and sometimes a mutilating procedure, such as high-frequency surgery, and this will have deleterious effects on the patient's health, without any benefit.'
In the Unified Health System, oncotic cytology has been replaced by the human papillomavirus DNA test, a genomic test designed to identify viral subtypes 16 and 18, which are responsible for 70% of cervical cancer precursor lesions.
In addition to its high specificity, the test can be performed every 5 years.
Andréia Gadelha, MD, a clinical oncologist and president of the Brazilian Group of Gynaecological Tumours, explained that patients who test positive should be closely monitored.
It is important to perform diagnostic tests and assess their clinical relevance. Therefore, continuing the screening of older patients is often not beneficial for the patients. According to Louise, these patients may no longer be candidates for curative treatments.
Other Cancers
Although screening strategies for cervical cancer are well established, other types of gynaecologic cancers require a different approach. Ovarian and endometrial cancers should not be routinely screened in asymptomatic women without a family history of the disease. 'There is no evidence that imaging tests reduce mortality from a population perspective,' said Cândido.
In these cases, imaging tests are not screening tools but serve as diagnostic aids when symptoms are present. 'If the patient has postmenopausal bleeding and endometrial thickening detected by ultrasound, the next step is to obtain a sample of the endometrium by biopsy,' explained Cândido.
'There's no need for an immediate biopsy if the lesion has completely benign characteristics and remains stable over time, if the complementary tests are reassuring, and if the patient is asymptomatic and at low epidemiological risk,' added Gadelha.
According to the gynaecologic oncologist, further investigation is warranted in cases involving a complex mass or abnormal vascularisation, persistent bleeding with endometrial thickening, high-grade cytology or glandular atypia, growth of an adnexal mass, or elevated biomarkers with suspicious findings.
'Early detection is beneficial when it improves the prognosis without causing unnecessary harm. This means selecting patients with relevant risk factors and avoiding screening in low-risk populations,' explained Gadelha, reinforcing that clinical practice must be based on updated evidence and recommendations.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Man Utd confirm deal for Wolves' Cunha
Manchester United have agreed a deal with Wolves for the signing of Brazil striker Matheus Cunha. The 26-year-old is set to become United's first signing of the summer after the club activated a £62.5m release clause in Cunha's Wolves contract. Advertisement The former Atletico Madrid forward will sign a five-year deal at Old Trafford, with the option of a further 12 months. Cunha was in Manchester over the weekend to complete a medical with the club. The deal, which is subject to visa approval and registration procedures, is expected to be completed once Cunha returns from international duty with Brazil later this month. Cunha left the Lowry Hotel in Salford on Sunday morning to join up with the national side. Brazil face Ecuador on Thursday (Friday 00:00 BST) in a World Cup qualifier, which will be Carlo Ancelotti's first game in charge. The forward scored 31 goals in 76 appearances for Wolves after completing a permanent move in 2023. Advertisement He joined the club in a £35m deal from Atletico Madrid, following a successful six-month loan spell the previous season. Ruben Amorim is keen to strengthen United's attack this summer after the club's worst-ever Premier League campaign - they finished in 15th.


Associated Press
3 hours ago
- Associated Press
Introducing Tempus One in the EHR with Integrated Guidelines
CHICAGO--(BUSINESS WIRE)--Jun 1, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the expansion of Tempus One—its generative AI clinical assistant—with direct integration into electronic health record (EHR) systems. By integrating AI at every point of the clinical care process, the expanded capabilities of Tempus One offer physicians in oncology and beyond more support in treatment decisions. Tempus One is uniquely positioned to offer these new features given the company's depth and scale of EHR integrations with providers across the U.S. Tempus has developed an integrated architecture that captures real-time clinical, molecular and imaging data from millions of patients and makes that data easily digestible and useful for clinicians and care teams. Through Tempus One, physicians can gain AI-enabled insights that transform how they interact with patient data, streamlining complex treatment decisions and reducing time spent on administrative tasks. New capabilities in the latest iteration of Tempus One: 'As healthcare faces rising costs and growing complexity, no group bears the burden more heavily than physicians and care teams,' said Ryan Fukushima, Chief Operating Officer at Tempus. 'This evolution of Tempus One represents a meaningful shift from a world where clinicians spend countless hours searching for answers and documenting care, to one where AI rapidly connects the dots across fragmented systems to deliver actionable insights in real time.' To learn more about Tempus One, view a video here and visit the website here. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the 'Securities Act'), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus One and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as 'anticipate,' 'believe,' 'contemplate,' 'continue,' 'could,' 'estimate,' 'expect,' 'going to,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' or 'would' or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled 'Risk Factors' in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on CONTACT: Erin Carron [email protected] KEYWORD: ILLINOIS UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: APPS/APPLICATIONS TECHNOLOGY HEALTH TECHNOLOGY SOFTWARE NETWORKS HEALTH GENERAL HEALTH ARTIFICIAL INTELLIGENCE ONCOLOGY SOURCE: Tempus AI, Inc. Copyright Business Wire 2025. PUB: 06/01/2025 08:30 AM/DISC: 06/01/2025 08:31 AM


Bloomberg
3 hours ago
- Bloomberg
AstraZeneca Breast Cancer Pill Slows Disease by Over Six Months
AstraZeneca Plc 's experimental breast cancer pill delayed disease progression by over six months, according to data from a new study that is likely to capture investors' attention. Camizestrant, in combination with other cancer medicines, helped patients with a specific type of breast cancer to live for a median of 16 months without their cancer progressing, compared with 9.2 months for those taking the current standard treatment.